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Abstract Upon emergence of modern anticancer therapy, medical community is divided into two opposite camps, one of
them claiming absolute necessity of using isolated or synthesized chemical compounds for efficient patient treatment and
another one advocating alternative cancer therapies, in particular those based on natural sources, including extracts from
plants. It seems, in reality, that the two camps are reconcilable: while natural sources, plant extracts or juices play both
curative and protective role, drugs represent the ultimate possibility to inhibit or reverse tumor development. In this paper
we tried to analyze anti-breast cancer potencies of quite a few extracts from different plant sources and to compare their
anti-proliferative efficiency of crude extracts with actions of their purified ingredients.
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1 Introduction
Breast cancer is the second overall cause of death for
women. Most therapeutic drugs (Fig. 1) are derived origi-
nally from plants, in particular flowers, fruits, fungi, and/or
lichens [1–15].
In the 1960s, scientists discovered that an extract from
the bark of the Pacific yew tree (Taxus brevifolia) could be
used to fight cancer. The toxic action of yew tree extracts
and even vapors emanating from the tree are known since
antiquity (taxon = poison). Its active substance, taxol
(Fig. 2), was found to be very efficient in arresting cell
cycle by blocking microtubules depolarization, and Ta-
xanTM is used at present as a drug of reference in esti-
mating activity of new substances destined for treatment of
breast and ovary cancers [16–19].
Other microtubule inhibitors or ‘‘tubulin interactive
agents’’, alkaloids vincrstine and vinblastine (Fig. 2), iso-
lated from Madagascar periwinkle Catharanthus roseus or
Vinca rosea, were found as well be efficient in breast
cancer treatment. The mentioned drugs are ones in hun-
dreds of naturally occurring substances used for centuries
to treat the disease and to promote health, and all the time
medicine relies mostly on plants, plant extracts, and other
plant products. The search for new anticancer agents of
natural and synthetic origin rests a very active field of
scientific activity, notably due to acquired single- and
multi- drug resistance of tumor cells, a relatively new
phenomenon appeared due to intense use of anticancer
compounds. Thus anticancer drugs which do not serve as
substrates for multidrug transporters, such as ‘‘breast can-
cer resistance protein’’, BCRP and ‘‘multi drug resistance
protein’’. P-glycoprotein, may considerably increase che-
motherapy efficiency [20–23].
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2 Plant Extracts as Potential Inhibitors of Breast
Cancer
Ancient Egyptians were the first to mention castor oil as a
medicine and since then this oil, also known as Palma
Christus, has been used as a folk medicine [15, 24, 25].
Castor oil packs had been highly popularized by Edgar
Cayce, ‘‘The Sleeping Prophet’’, who recommended, in
particular to eradicate tumors near the breast surface. The
seed oil from the castor bean Ricinus communis is very rich
in D-12-hydroxy-9-octadecenoic acid (ricinoleic acid,
about 90 %, Fig. 3), and contains as minor components
phenolic compounds, such as p-coumaric acid, ferulic acid,
o-coumaric acids, syringic, cinnamic, chlorogenic, neo-
chlorogenic, and gallic acids [26–29]. Quite a few of tri-
glycerides of R. communis containing ricinoleic acid, have
as major components triricinolein (Fig. 4) and, in addition,
diricinoleo-triglycerides with ricinoleic acid at the 1- and
3-positions (Fig. 3) [30]. Castor oil is hydrolyzed in the
small intestine by pancreatic enzymes, which results in the
release of glycerol and ricinoleic acid, although 3,6-epox-
yoctanedioic acid, 3,6-epoxydecanedioic acid, and 3,6-ep-
oxydodecanedioic acid (Fig. 4) also appear metabolites.
Castor oil and ricinoleic acid easily penetrate deep into the










































Fig. 1 Selected anti-breast cancer agents isolated from different plant species
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According to estimates of the World Health Organiza-
tion, 80 % of the world population, especially those living
in Asia, Latin America and Africa, still relies on herbal
medicine [31–36]. No wonder that screening of natural
sources for different kinds of biological activity and
medicinal potency are performed mostly on indigenous,
often exotic plants. Quite often, an anti-proliferative
activity of the plant extracts revealed in studies in vitro was
not associated with the medicinal effects of herbal formu-
lations used by local herbalists.
Vernonia amygdalina (VA), is an edible African
mountain plant of the Asteraceae family. It is known as
‘‘bitter leaf’’, eventually due to high amounts of alkaloids,
saponins and tannins [37]. The leaves and the roots of this
shrub are used in sub-Saharan Africa for many purposes,
e.g. as a tonic, but also to improve digestion, to reduce
fever, and to protect organism from intestinal parasites and
dermatomes. V. amygdalina extracts was also found to
inhibit proliferation of breast cancer MCF-7 cells [37].
Extraction of VA with multiple solvents of various polarity
indexes yielded three fractions (A1-2, B-3) that signifi-
cantly inhibited cell growth (P \ 0.05) at 0.1 mg/mL. At a
higher concentration (1 mg/mL), six fractions extracted by
hexane, chloroform, butanol, and ethyl acetate inhibited
DNA synthesis by 76–98 %. Obtained fractions inhibited
also the growth of MKL-F breast cancer cell line [30, 37].
Interpretation of these effects is not simple since V. amy-
gdalina leaf extracts contain quite a few potentially anti-
cancer active ingredients of different functional and
structural properties, such as antioxidants (flavonoids),
lipophilic terpenoids (sesquiterpene lactone), and amphi-
philic saponins.
An Amazon shrub Suma (Pfaffia paniculata), also
nicknamed Brazilian ginseng and ‘‘para tudo’’ (‘‘for
everything’’), is used in folk medicine as tonic and assures
resistance to stress. On the other hand, extracts from Suma
bark or roots were found to possess cytotoxic activity. P.
paniculata contains in particular pfaffic acid, and saponins
pfaffosides A–G (Fig. 5). Toxicological properties of sap-
onins present in different edible plants are wildly recog-
nized. It is supposed that these surface-active glycosidic
compounds could be in part responsible for well docu-
mented anticancer actions of roots of Suma [38–40]. A
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Fig. 3 Structures of ricinoleic acid and epoxy dicarboxylic acids
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butanolic extract from Suma roots were found to be cyto-
toxic against MCF-7 cells, starting from the concentration
of 0.4 mg/mL [41]. Though damaging of cell and mito-
chondrial membranes and nuclear structure was observed,
detailed mechanisms of action of the extracts on the cancer
cells remain to be investigated.
In some screening studies, the portion of potentially
useful plants was found to be extraordinary high. Thus 32
plants were collected in the rain Malaysian forests and 143
crude extracts were evaluated for their anti-proliferative
activities on two breast cancer cell lines, i.e. MCF-7, the
most commonly used model of estrogen-positive breast
cancer line, and T47D cells. After performing sulforhoda-
mine-B assay, 13 crude extracts from 11 plant species were
found to possess an anti-proliferative activity (IC50 for
dried extracts was 0.1 mg/mL or lower) [42].
One has to realise that chances to identify really efficient
anti-cancer plant extracts are quite low. Indeed, how many
plants can be considered as potential sources of active
compounds? What is a dose value corresponding to a
borderline between extract potency and inefficiency? Two
studies mentioned below partially clarify the incertitude.
Brazilian rain forests are characterized by the excep-





















Fig. 4 Bioactive di- and triacylglycerides of ricinoleic acid
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periodically attempts have been made to perform the global
screening of extracts from the plants in search of poten-
tially active compounds. Thus more than 1000 aqueous and
organic extracts of 351 species were checked at a dose of
0.1 mg/mL for their capacities to suppress growth of
MCF7 cells. Surprisingly, only 11 extracts revealed marked
cytotoxicity at this the relatively high dose [43].
Another pharaoh study was undertaken in 8-year
screening of South African plants [44]. Of a total of 7500
plant extracts screened on 60 human cell lines, the most
active were further tested on MCF7, renal cancer and
melanoma cell lines. The extracts were separated into 4
groups, according to TGI (total growth inhibition) values:
[50 lg/mL (inactive), 15–50 lg/mL (weak), 6.25–15 lg/
mL (moderate) and\6.25 lg/mL (potent). Of total of fifty
active extracts neither was found to be potent in MCF7 test,
and only twenty presented moderate inhibiting activity. At
first sight, the conclusions from these two screening studies
seem to be frustrating. Nevertheless a labor-consuming and
often altruistic approach dealing with the testing of crude
plant extracts quite often leads to identification of active
compounds and revealing cellular mechanisms involved in
the cytotoxic actions [44].
Withania somnifera (Indian ginseng) is a popular shrub
used in Asian traditional medicine, having a 3000 years
history. The organic extracts from W. somnifera (Solana-
ceae) were tested among two dozens selected plant species,
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Fig. 5 Bioactive saponins pfaffosides A–G isolated from an Amazon shrub Suma, Pfaffia paniculata
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values obtained after 24 h treatment of cell cultures with
the extracts were 150 and 60 lg/mL on for murine fibro-
sarcoma cell line L929sA, known for its sensitivity to TNF,
and MCF7, an ER positive control cell line, respectively.
At least two cytotoxic pathways seem to be activated by the
W. somnifera extract. Among the active constituents in
W. somnifera leaves and roots quite a few C28-steroidal
lactone triterpenoids, withanolides (Fig. 6), were identified
[47]. Thirteen withanolides were evaluated using antioxi-
dant and cyclooxygenase enzymes inhibitory bioassay-
guided test performed on four different cell lines, including
MCF7. Three of the withanolides were found to be as
efficient as adriamycin (Fig. 7), giving IC50 values between
0.23 to 0.40 lg/mL. Withaferine A inhibited growth of
breast and colon cancer cell lines event more efficiently
than this anticancer drug of reference.
3 Effects of Diet Flavonoids on Breast Cancer Initiation
and Progression
There are numerous reports that a diet rich in flavonoids
may be protective against various types of cancer, from
ovarian cancer to lung and pancreas cancers. Nearly 5000
flavonoids were identified in fruits and vegetables. Flavo-
noids of reference genistein (principle isoflavonoid of soja)
and quercetin (present at large amounts in the skins of
apples and red onions) have been shown to inhibit tumor
cell growth. Though animal and cell culture studies indi-
cate that tumor-preventive effects of electron donor flavo-
noids are due to their free radical scavenging properties
[48, 49], concrete molecular mechanisms for anticancer
activity of each active flavonoid are still to be revealed.
The spectrum of flavonoid effects spreads from inhibition
of cyclin-dependent kinases (CDKs), which are critical for
cell growth and division, to blocking angiogenesis and
modulating MDR1 activity. For instance, genistein (Fig. 1)
was found to be very efficient in inducing apoptosis in
MCF-7 and T47D breast cancer cell lines [50]. It is to
mention that large-scale clinical trials did not provide
decisive conclusions that these antioxidants prevent cancer
or slow down the disease. The whole area dealing with
health benefits of antioxidants and in particular their anti-
cancer activity enters in turbulence. Indeed, free radical
scavengers would protect DNA from damages and prevent
cell transformation into malignant type, but on the other
hand they may improve cell survival. This double-face
nature of antioxidants has been revealed in recent studies
showing protective influence of antioxidants on tumor
cells. In particular, in extracellular matrix-deprived human

























Fig. 6 A few bioactive C28-steroidal lactone triterpenoids, withan-
















Fig. 7 Adriamycin also known as adriacin, adriblastin or adriblastina
is an antitumor antibiotic was isolated from Actinomadura roseola
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oxidation, and thus restored ATP synthesis and prevented
non-apoptotic cell death [51].
Among most extensively investigated flavonoids,
flavopiridol, catechins, genistein and quercetin are known
to prevent cancer and possess anti-tumour activities.
Flavopiridol (Fig. 8), also known as alvocidib, HMR 1275
and/or L 86-8275 is a semisynthetic flavone derivative of
the natural anti-inflammatory and immuno-modulatory
alkaloid rohitukine [52]. Rohitukine (Fig. 8) was isolated
for the first time from Amoora rohituka (family Meliaceae)
in 19 [53, 79] and later from Schumanniophyton magnifi-
cum [54], and Dysoxylum binectariferum [55]. Rohitukine
showed moderate cytotoxicity against human HL-60 pro-
myelocytic leukemia and HCT-116 colon cancer cells [56].
After replacement of a methyl group by the chlorophenyl
moiety at position 2 of rohitukine, additional pharmaco-
logical properties were acquired: [57, 58] from inhibition
of different CDKs, thus inducing apoptosis, to modulation
of the immune response. In the breast carcinoma MCF-7
cell line, flavopiridol produced arrest of cell cycle in G1,
and this action was not dependent on functional p53 [59]. It
is to mention that flavopiridol was the first CDK inhibitor
to be tested in clinical trials [60].
Another example of a polyphenol which exerts both cell
protecting and cancer cell killing effects is quercetin
(Fig. 1). This flavonoid present in high amounts in some
fruits and vegetables is suggested to exert these opposing
actions by playing a role of an antioxidant due to metal
chelating and scavenging free radicals, and a role of pro-
oxidant due to its ability to generate ROS. The latter spe-
cies may a priori induce DNA damage [61]. Numerous
effects of quercetin on breast cancer cell functions were
reported, from inducing p21 (CDK inhibitor) and arrest of
cell cycle in G1 or G2/M [62] to apoptosis which could be
due to caspase activation, microtubules modification and an
increase of stress proteins expression [61]. No studies were
done on tissue level. Concerning results obtained in vitro,
in most studies performed on breast cancer cell lines this
flavonoid was tested at high concentrations, ranging from
10 to 200 lM. For example, at a relatively high concen-
tration (10 lM) quercetin induced only mild DNA damage,
and 94 % of SK-Br3 cells were still viable even after 4-day
incubation at this quercetin concentration [61].
To evaluate potential anticancer activities of dietary
flavonoids, such as quercetin, one has to compare plasma
levels of the ingested natural compound with those used in
studies on cancer models. Though only 0.35–1.4 % quer-
cetin ingested at breakfast is excreted in 24 h, its peak level
in blood plasma rests quite low: 0.6 lM (apple consump-
tion) and 0.74 lM (onion consumption) [63]. Taking into
consideration that consumption of a single onion portion
would correspond to intake of about 200 lmol quercetin,
one may conclude that a major fraction of the flavonoid is
either metabolized or absorbed by the tissues.
Apple consumption has been documented to decrease
risk a number of chronic diseases, from coronary heart
disease to cancer. It is to mention that constituents of apple
flesh and apple peel differ considerably. A bioactivity-
guided fractionation of Red Delicious apple peels allowed
to isolate and characterized twenty-nine compounds,
including triterpenoids, flavonoids, organic acids and plant
sterols [17]. The major flavonoids in apple peels were














Fig. 8 Two anti-breast cancer alkaloids: rohitukine was isolated from
Amoora rohituka, flavopiridol is a semisynthetic flavone derivative
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Fig. 9) and quercetin-3-O-b-D-galactopyranoside (17.1 %,
Fig. 9) but, surprisingly (structure see on Fig. 1), not
quercetin (0.2 %). When tested on cancer cell lines quer-
cetin and quercetin-3-O-b-D-glucopyranoside inhibited
proliferation of HepG2 and MCF-7 cells with EC50 values
of 41 and 49 lM for HepG2 cells and 137 and 24 lM for
MCF-7 cells, respectively. Concerning possible antioxidant
impact of the isolated phenolic compounds, antioxidant
activities of caffeic acid, quercetin, and quercetin-3-O-b-D-
arabinofuranoside (EC50 values\10 lM) were comparable
with that of vitamin C.
Attempts were made to correlate anti-cancer efficiencies
of apple extracts with those of individual compounds. One
of the studies [64] indicates that apple extract and quer-
cetin-3-b-D-glucoside (Q3G) possess anti-proliferative
activity against MCF-7 cells (the corresponding EC50
values being 71 lg/mL and 46 lM). Two-way combina-
tion of apple extracts plus Q3G significantly increased anti-
proliferative action on the cells. The EC50 values were
reduced to 33.8 lg/mL and 10.8 lM, respectively. One has
to emphasize that the comparison of efficiencies of crude
extracts and their individual ingredients is possible only on
wt/volume bases. In this case the latter study would indi-
cate that the apple extract possesses higher anti-prolifera-
tive than Q3G. Indeed using wt/volume EC50 values (71
and 29 lg/mL, respectively) and taking into consideration
very low levels of Q3G in apples [64], one may conclude
that the latter quercetin analog should be excluded from the
list of potential anti-cancer drugs. Unique synergetic
influences of the compounds existing in edible, plants
reinforce position of the followers of alternative medicine.
At present, we lack a straightforward evidence of the
link between anti-proliferative efficiency of an edible plant
ingredient in vitro and its anticancer activity in vivo. For
example, Mediterranean diet, characterized by high con-
sumption of fruits and vegetables, is traditionally consid-
ered to be one of the healthiest, providing organism
protection against cardiovascular diseases and cancer.
Numerous studies indicate that extracts from edible plants
from Mediterranean areas possess anti-proliferative activity
when evaluated on different cancer cell lines. Using the
sulforodamine B assay, extracts from sixteen plants, eaten
boiled, fried or fresh in Southern Italy, were tested on four
human cancer cell lines, including MCF-7 [65]. No clear
correlation was obtained between the level of flavonoids
and the inhibitory effects. Thus Sow thistle Sonchus ole-
raceus with the highest flavonoid content (33 mg/g of dried
extract) was found to be less efficient (8.4 % inhibition at
100 lg of hydroalcoholic extract/mL) than Wild artichoke
Cynara cardunculus (9 mg/g and 22.7 %) or caper Capp-
aris sicula (2.52 mg/g and 42.67 %), very rich in quercetin.
On the other hand, extracts from water mint Mentha aqu-
atica showing the best antiproliferative activity on MCF-7
cell line (44.7 % inhibition) were characterized by a rela-
tively high flavonoid levels (15.75 mg/mL) and an
extraordinary high total phenolic content (337 mg/g).
Another example of a double-face nature of quercetin
and the whole class of flavonoids is associated with their
structural resemblance to cell estrogens. Estrogen receptors
are one of the targets in anti-breast cancer therapy.
Flavonoids from medicinal plants are considered as weak























Fig. 9 Major flavonoids from apple peels are known as anticancer
agents
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High phytoestrogen consumption is a priori beneficial for
postmenopausal women though no straightforward data is
yet obtained on their relieving actions on menopausal
symptoms. The review of epidemiological data as well as
in vitro experiments on ER-positive and ER-negative
breast cell lines [66] allowed to postulate that phytoestro-
gens may exert two opposite actions, depending on their
level in blood and concentrations used in experimental
studies: At concentrations, not exceeding 10 lM, some
phytoestrogens, like genistein, stimulate growth of ER-
positive MCF-7 and T-47D cell lines, but not the ER-
negative MDA-MB 231/435 breast cancer cell lines. At
higher concentrations survival of both types of breast
cancer cells of both types decreases. At low doses the
phytoestrogens, as ligands of ER, are likely to stimulate
directly metabolic pathways providing and/or improving
cell proliferation, in particular progression of cell cycle and
apoptose inhibition. At higher concentrations, mechanisms
which are not dependent on ER signaling, including those
associated with prooxidant properties of the flavonoids
seem to be triggered. Overall, taking into consideration
potential increase of the risk of tumor progession in the
presence of circulating RE ligands, decreasing consump-
tion of phytoestrogens as supplements, or those present at
high amounts in soy, would be rather beneficial for quite a
large women’ population [66].
4 Juices as Sources of Potential Inhibitors of Breast
Cancer
Phenolic compounds and their glycosides are constituents
of many fruits and vegetables, and they have attracted a
great deal of public and scientific interest because of their
potential anti-carcinogenic and other health-promoting
effects as antioxidants [2, 3, 5, 67, 68].
The benefits of a plant, probably most often mentioned
in literature, olive tree, for health are known from Bible
times. However, in most cases beneficial effects olive oil
are emphasized taking in mind high contents of monoun-
saturated fatty acids, such as oleic acid (comprising
50–80 % of total FA) in the fruits. Since the olives are also
known to be rich in polyphenolic antioxidants, preventive
anti-cancer properties of olive oil described in medical
literature are most likely due to DNA protection from
reactive oxygen species (ROS).
Two Spanish groups investigated anti-cancer potencies
of extra virgin olive oil (EVOO). In one of the studies [69]
effects of dietary EVOO on experimentally induced rat
mammary adenocarcinomas were compared with those
obtained on animals placed on corn oil diet. Tumors from
rats fed the olive oil diet were characterized by a more
benign phenotype, while those from rats on corn diet were
found to be more aggressive. Moreover the olive oil diet
decreased activation of proto-oncogene p21Ras and
upregulated the Raf/Erk pathway, compared with the
control, whereas the corn oil diet did not modify Ras
activity and enhanced the Raf/Erk pathway. It was con-
cluded that two types of oil diets exerted their effects
through a different proliferation/apoptosis balance and
probably distinct levels of DNA damage.
The olive oil contains dozens of polyphenol, including a
strong polyphenolic antioxidant oleuropein and its hydro-
lyzed derivatives. Anticancer efficiencies of the quantita-
tively minor phenolic components of EVOO polyphenols,
traditionally overshadowed by oleic acid, were tested on
MCF-7 (HER2-negative), MCF-7/HER2 and HER2 gene-
amplified SK-Br3 breast cancer cell lines [70]. The cell
cultures were incubated in the presence of tyrosol, hy-
droxytyrosol, oleuropein glycoside, and oleuropein agly-
cone (Fig. 10) at concentration ranging from 6 to 100 lM.
The first three polyphenols did not change or modified only
slightly viability of the cells, and only oleuropein aglycone
produced effects at doze-dependent manners, with IC50
values about 50 lM for MCF-7/HER2 and SK-Br3 cell
lines. When tested in Cell Death ELISA test, oleuropein
aglycone at 25 lM increased apoptosic cell death by factor
1.5 (MCF-5), 2.5 (MCF-7/HER), and 4 (SK-Br3). The
authors suggested that an extraordinary anti-oncogenic
efficiency of olive oil may be due to actions of both phe-
nolic and fatty acid components. In fact, olive oil is char-
acterized by a unique fatty acid composition (very high
level of oleic acid and a low ratio (x-6)/(x-3) polyun-
saturated FA), which in the combination with oleuropein
aglycone provide marked down-regulation of a proto-
oncogenic HER2.
American cranberry (Vaccinium macrocarpon) which is
very rich in phenolic compounds such as flavonoids,
anthocyanins, proanthocyanidins and small phenolic acids
has one of the highest free-radical scavenging capacity. It
has been shown that 20 h incubation of human breast








Fig. 10 Anticancer agent oleuropein aglycone isolated from virgin
olive oil
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lines) in 6.7 % cranberry juice induced death of 20 % of
cell population [71, 72].
The genus Citrus includes several species, from sweet
orange (S. sinensis) to mandarine (C. reticulate) as well as
and multiple hybrids, represents an extraordinary source of
flavonoids, and their content in the fruit juices is as high as
1 lg/mL [73]. In previous years most attention has been
attracted to citrus flavonoids due to their anti-inflammatory
effects and their ability to decrease capillary permeability.
Recent studies are focused as well on preventing cancer
development by the fruit juices, fruit extracts and indi-
vidual compounds isolated from the citrus. The major cit-
rus flavonoids include quercitrin (quercetin-3-O-
rhamnoside), rutin (quercetin-3-O-rutinoside), tangeritin,
and hesperidin.
Anticancer actions of hesperidine and naringenin
(Fig. 11) were compared with those of other flavonoids of
noncitrus origin, including quercetin [74]. When studied on
a human breast cancer cell line MDA-MB-435, the tested
flavonoids inhibited the cell proliferation at doses varying
from 6 (noncitrus baicalein) to 140 lg/mL. Synergistic
actions of one-to-one combinations of quercetin with hes-
peretin and naringenin (with ID values decreasing to
4.7 lg/mL) and naringenin plus hesperetin were also
demonstrated.
The discovered synergism may be due to different
inhibiting pathways activated by the studied compounds. In
another study, inhibiting effects of double strength orange
and grapefruit juices on DMBA-induced mammary rat tu-
morogenesis were compared [75]. In spite of the fact that
naringenin and hesperetin are present in oranges and
grapefruits at similar concentrations, the juice from oranges
was more effective than grapefruit juice. The results of
these two studies confirm widely spread, rather intuitive
than scientifically justified, belief that active compounds
are more effective when consumed from crude extracts
than in isolated forms (for update concerning numerous
effects of citrus flavonoids and possible mechanisms of
their action, see review [76]).
Beliefs in miraculous folk medicine may complicate
sober appreciation effects of crude extracts. Thus a tradi-
tional Tahitian medicinal plant Morinda citrifolia (noni) is
believed to produce numerous therapeutic effects, from
hypotensive and anti-inflamatory actions to antitumor
activity. This plant has also been reported to have anti-
bacterial, antiviral, antifungal, anti-helmint and analgesic
activities. Though active compounds of the plant had not
been identified, essays have been performed to test its
anticancer efficiency. Thus methanol extracts obtained
from the fruits of noni were verified for cytotoxic activity
using different cancer cell lines. At concentration of
0.1 mg/mL, the crude extract demonstrated very little
cytotoxicity to BHK, Hep2, and Vero cells while its
cytotoxic activity was found to be pronounced in experi-
ments on neuroblastoma (LAN5) and MCF-7 cell lines
[77]. Fruit juice from M. citrifolia was shown to treat breast
cancer as well to inhibit the metastases and even to destroy
metastasized breast cancer cells, see corresponding patent
[78].
The choice between juice (extracts) from the plants and
individual compounds as means to realize effective anti-
tumor therapy is painful, especially in case of major
women’s killer, a rapidly developing breast cancer. It has
to emphasize, however that numerous data have been
accumulated during hundreds of years indicating great
efficiency of preventive measures, including ‘‘anticancer’’
diets and crude preparations from a large variety of vege-
tables. An example is the genus Brassica (including wild
cabbage, cauliflower, Brussels sprouts and broccoli) [79].
Some reports indicate a breast cancer specific action of
juices from this plant. Mechanism of antitumor effects of
the juices from varieties of Brassica is not completely
understood, though it is attributed mainly to actions of
indole compounds (mainly indole-3-carbinol and sulfora-
phane, Fig. 12) which induce expression of detoxification





















Fig. 11 Two anti-breast cancer (MDA-MB-435) compounds: na-
ringenin also known as 40,5,7-trihydroxy-flavanone, S-dihydrogeni-
stein, salipurol, or salipurpol, and second - hesperidin also known as
7-(6-O-a-L-rhamnosyl-D-glucoside), atripliside B, cirantin or hespere-
tin 7-rhamnoglucoside, isolated from grapefruit and orange,
respectively
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performed on MCF-7 (ER?) and MDA-MB-231 (ER-)
breast cancer cell lines, the cells were pretreated with
increasing concentrations of crude Brassica olearacea
juice for 72 h which was followed by pulses of [3H]thy-
midine and determination of its incorporation into DNA
[80]. The effects on DNA synthesis were dose dependent,
and 50 % inhibition was observed at 5–30 mL/L. The IC50
for MCF-7 cells was 5 mL/L (with a nearly complete
inhibition at 30 mL/L, whereas for other cell lines (Vero,
Hep2, ECV30) IC50 values were as high as 40 mL/L. It
seems that both apoptosis and necrotic pathway are acti-
vated in breast cancer cells in the presence of active
compounds from the cabbage juices and these pathways do
not require expression of estrogen receptors.
Another study indicates that compounds present in
cruciferous vegetables may produce opposite effects on
estrogen positive cells. Ethyl acetate extracts from cabbage
and Brussels sprouts were analyzed for their estrogenic and
anti-estrogenic activity by following estradiol-induced
proliferation of MCF-7 cells and changes in the level of
estrogen-responsive pS2 mRNA. At low doses (5–25 ng/
mL) the extracts inhibited the proliferation and decreased
pS2 gene expression. However higher concentrations
(50 ng/mL–25 lg/mL) increased MCF-7 proliferation [81].
It has been concluded that though both estrogenic and anti-
estrogenic compounds seem to be present in cruciferous
vegetables, it is not likely that concentrations stimulating
estrogen-dependent breast cancer growth could be attained
in organism.
5 Anti-cancer Properties of Teas and Coffee
Epidemiologic evidence of preventive and curative poten-
tial of tea (Camellia sinensis) is not consistent. This may be
explained by large varieties of tea consumed in Western
countries (predominantly black tea) and in Asian countries
(green tea). Meanwhile, anticancer properties of green tea
are known for many years, and they are presumably due to
high content of water-extractable polyphenols which is
5–10 times lower in an oxidized green tea derivative
obtained after fermentation (black tea) [82].
Mechanisms underlying these green tea’s properties
may include arrest of cell cycle in G1, increase of apop-
tosis, antioxidant and anti-estrogenic actions. Green tea
extracts were shown to have synergetic action with a
conventional anti-estrogens drug, tamoxifen. When tested
on estrogen receptor-positive MCF-7, ZR75, T47D human
breast cancer cells combinations of tea extracts and the
drug were found to be more effective in suppressing the
cell proliferation than either agent given alone [83]. These
data are of potential clinical value since relative effects of
the tea extracts were the most pronounced at law doses of
tamoxifen, which a priori allows to make more drug ther-
apy harmless and more efficient. Here, it is to mention that
green tea flavonoid epigallocatechin gallate (EGCG,
Fig. 13) inhibits P-glycoprotein, and the EGCG effects
were found to exceed those of quercetin (Fig. 1) and
verapamil (Fig. 2) [84].
Direct pro-apoptotic effects of green tea extracts and tea
catechins on tumor cells in vitro and in vivo were also
demonstrated. When tested on different breast cancer cell
lines, EGCG revealed a modest pro-apoptotic activity.
However, treatment of 4T1 cells with EGCG in combina-
tion with taxol led to a dramatic increase in cell apoptosis
compared to treatment with taxol alone [85]. The chemical
structure of EGCG provides its ability to be a metal che-
lating agent, and to possess, depending on its concentra-
tion, either pro- or antioxidant activity. Different actions of
EGCG were summarized in a review [86]. Other studies
also indicate that green tea inhibits angiogenesis. It was
demonstrated that crude green tea extracts and EGCG, the
main green tea polyphenol, decreased in a dose-dependent
manner transcription of vascular endothelial growth factor
(VEGF) and inhibited MDA-MB231 breast cancer cell and
human umbilical vein endothelial cell (HUVEC) prolifer-











Fig. 12 Main compounds of juice from Brassica olearacea
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angiogenesis which was manifested by decreased necrosis
areas and lower blood vessel density in the treated xeno-
grafts [83].
In a 7-year study on 472 patients with I-III stages of
breast cancer it was shown that increased consumption of
green tea, 4–5 cups per day, was associated with decreased
numbers of axillary lymph node metastases in the group of
premenopausal patients with stages I and II and an
increased expression of progesterone and estrogen recep-
tors among postmenopausal ones. It was significantly
associated with improved prognosis of stage I and II breast
cancer, while no improvement in prognosis was observed
in stage III breast cancer [87]. In a long term population-
based, case–control study [88], breast cancer risk was
related with initiation of green tea consumption and men-
opausal status. In the group of premenopausal women, a
direct relationship was found between the reduced risk and
years of green tea drinking as well as amount of monthly
consumed tea. Surprisingly, among postmenopausal
women decreased risk of breast cancer was associated with
an older age of initiation of the tea drinking. Globally, this
study indicated that regular green tea consumption was
weakly inversely associated with breast cancer risk [89].
A joint US-South Korean team estimated contents of
different flavonoids in 15 commercial teas, including black
and green teas and compared anticarcinogenic actions of
individual tea compounds, such as nine green tea catechins,
three black tea theaflavins, as well as extracts of the same
tea leaves. Most tested compounds and all tea extracts
inhibited growth of MCF-7 cell line. Other cell lines
(colon, liver and prostate cell lines) were also inhibited.
One of the conclusions from this study was that levels of
the tea flavonoids did not directly correlate with anticancer
activities. In addition, both green and black teas were found
to possess similar anticancer potentials. In any case, con-
sumers may benefit more by drinking both green and black
teas [90].
Conflicting results obtained in epidemiological studies of
black tea and coffee effects on development and progression
of breast cancer may be due to shortcomings in precised
control of hormone receptor status as well as in neglecting
such factors as smoking, the dietary habits and frequency of
daily intake. A Swedish group prospectively followed 61433
women who were cancer free in 1987–1990 and some of
them later developed invasive breast cancer [91]. The results
of this study indicate that black tea consumption may be
positively associated with risk of ER?/PR? tumors. The
mentioned study revealed as well a non-significant correla-
tion between increased coffee intake and breast cancer risk
in ER? group and inverse correlation in ER- group. More
recent Swedish study provided strong evidence that coffee
consumption decreased overall breast cancer risk of breast
cancer. The risk decreased by 57 % (P = 0.0003) and 33 %
(P = 0.034) For women who consumed more than five cups
of coffee per day were the risks were 57 % (P = 0.0003)
and 33 % (P = 0.034) in ER-negative and PR-negative
groups disease, respectively [92]. No reduction in the inci-
dence of breast cancer risk was found in ER-positive group.
6 Wine as a Source of Potential Inhibitors of Breast
Cancer
Grapes, one of the most popular fruits and the most widely
cultivated throughout the world, contain large amounts of
phytochemicals including anthocyanins and resveratrol
(Fig. 1), which offer health benefits [93]. The beneficial
health-related effects of phenolics in grapes are of impor-
tance to consumers, breeders and the grape industry.
Red wine is a rich source of polyphenolic components.
The inhibitory effects of red wine polyphenolics on human
breast cancer cells have been demonstrated earlier by many
authors [94–98]. Grapes phenolics, flavonoids and resve-
ratrol, from Pinot Noir, Cabernet Franc, Chardonnay,
Catawba, Concord, Sheridan, Niagara and Riesling wines
significantly inhibited the proliferation of Caco-2, HepG2
and MCF-7 human cancer cells [95]. Flavonoid fractions
from red wine Merlot showed maximal inhibition of the
growth of breast cancer cells, with relatively low cyto-
toxicity towards human mammary epithelial cells (HMEC)
and human breast cancer (MCF-10A) cells [99], and MCF-













Fig. 13 EGCG (also known as epigallocatechin gallate, epigalloca-
techin-3-monogallate, L-epigallocatechin gallate, epi-gallocatechin
3-O-gallate or epi-gallocatechin gallate) is the main green tea
polyphenol
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Punicic acid (also known as trichosanic acid) is a long
chain polyunsaturated fatty acid 9c,11t,13c-18:3 (Fig. 14)
found in Punica granatum (pomegranate) seed oil (up to
80 %), extracts, and pomegranate red wine (Armenia).
Pomegranate red wine contains up to 3 times more anti-
oxidants than red wine [101]. One of the studies shows that
pomegranate helps to slow down progression of prostate
and breast cancers. Proliferation was inhibited 92 and 96 %
for MDA-MB-231 and MDA-ERa7 cells, respectively
compared to untreated cells by 40 lM punicic acid [102].
The traditional Chinese medicine wine usually manu-
factured from (wt%): Venenum bufonis (10–30), Typhoni-
um giganteum (20–40), snake (10–30), and Buthus
martensii (10–30) by slicing or pulverizing, soaking in hard
liquor, and adding honey. This Chinese medicine wine can
be used for treating breast cancer and pancreas cancer
[103]. A health Chinese wine from tomato contains (wt%):
wine yeast (1), tomato (25–30), white granulated sugar
(3–4), and spice (0.5–1.0) [104]. The high-tomatine green
tomato extracts strongly inhibited the following human
cancer cell lines: breast (MCF-7), colon (HT-29), gastric
(AGS), and hepatoma (liver) (HepG2), as well as normal
human liver cells (Chang). The tomato glycoalkaloid a-
tomatine (Fig. 15) was highly effective in inhibiting MCF-
7 and all other tested cell lines [105].
7 Concluding Remarks
From this hardly exhaustive review, one can make quite a
simple conclusion [106–109]. The rejection of the con-
ventional cancer treatment by the followers of traditional

































Fig. 15 a-Tomatine also known as spiro[8H-naphth[20,10:4,5]indeno
[2,1-b]furan-8,20-piperidine], b-D-galactopyranoside derivative; spiroso-
lane, or lycopersicin, is strong inhibitor of human breast (MDA-MB-231).







Fig. 16 Rotenone is a naturally occurring compound extracted from





Fig. 14 Rare natural acid, punicic acid (9c,11t,13c-18:3) from
Punica granatum
Modern Anticancer Therapy 13
123
humans and every animal species: each plant and juice that
could be consumed is safe. Quite often, however the tra-
ditionalists try to avoid another fact: the active plant
ingredients in most cases represent toxins killing the cell,
like taxol. Some of toxins derived from plants target
numerous metabolic pathways. One of the examples is well
known inhibitor of mitochondrial electron transport chain,
rotenone [114–117].
In the nineteenth century, travelers in equatorial coun-
tries provided reports on the use of certain plants,
belonging to the family Fabaceae, or Papilionaceae, for
catching and killing fish. The fish poisoning plant ingre-
dient was later identified as isoflavonoid. This ‘‘ichthyo-
cide’’, rotenone, has been widely used in solution as a
pesticide and insecticide.
Acting as a specific inhibitor of mitochondrial NADH
dehydrogenase rotenone (Fig. 16) may increase the gen-
eration of ROS which represent an important proapoptotic
factor. Indeed rotenone at micromolar concentrations was
found to induce apoptosis in MCF-7 cells and this effect
was attenuated in the presence of an antioxidant. The
molecular mechanisms underlying the rotenone-induced
effects were attributed to JNK and p38 MAPKs pathways
activation and the inactivation of extracellular protein
kinase 1/2 (ERK1/2). In addition, it increased level of
apoptotic protein Bax while the level of antiapoptotic
protein Bcl-2, was found to be decreased in the presence of
rotenone in a time-dependent manner [107].
Traditional and modern approaches for prevention and
treatment cancer may co-exist being complementary.
Indeed, numerous tests on cancer cell survival and prolif-
eration revealed strong additive or synergistic effects of
combinations anti-cancer drug/extracts from a plant that
may decrease unspecific toxicity of anticancer drugs. The
synergistic action can not be reasonably explained without
knowledge of the exact composition of presumably active
ingredients in the extracts and juices. This action could be
due to increased bioavailability or stability of the anti-
cancer drugs, activation or inhibition of metabolic path-
ways modifying levels of pro- and anti-apoptotic proteins.
In any case, in vitro experiments on cancer cell lines have
to be confirmed by clinical studies.
Another probably less substantiated remark is that ‘‘safe’’
plant extracts would help cells to survive under conditions
which progressively break intracellular machinery (one may
mention free radical scavenging activities). On the other
hand, the most efficient modern drugs kill cells, without
discriminating normal and cancerous cells (to mention here
free radical attacks). No matter that cancer cell, due to their
extraordinary proliferative activity, are more vulnerable to
DNA damaging or cell cycle blocking agents. A single
healthy cell mutation can provoke its transformation into a
malignant phenotype. In any case, combinations of drug
treatment and traditional medicine have no sense and in some
situation could be harmful for the patient.
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